Table 1 Baseline characteristics

From: Potential impact of renin–angiotensin system inhibitors and calcium channel blockers on plasma high-molecular-weight adiponectin levels in hemodialysis patients

 

CKD

HD

 

Men

Women

Men

Women

Number

16

12

90

54

Age (years)

62.7±15.4

61.8±8.6

61.3±10.9

59.7±13.0

Duration of dialysis (mean)

133.8±107.5

178.6±105.8

Hypertension

13 (81%)

10 (83%)

74 (82%)

42 (78%)

Diabetes

5 (31%)

6 (50%)

32 (36%)

12 (22%)

Dyslipidemia

7 (44%)

9 (75%)

51 (57%)

40 (74%)

Smoking

8 (50%)

3 (25%)

40 (44%)

12 (22%)

Previous CVD

6 (38%)

3 (25%)

25 (28%)

12 (22%)

Systolic BP (mm Hg)

140±19

138±20

148±23

145±19

Diastolic BP (mm Hg)

78±15

77±14

84±16

82±13

Hemoglobin (g dl−1)

12.3±2.0

10.6±1.5

10.9±1.3

10.4±1.0

Hematocrit (%)

36.1±4.9

32.2±3.6

32.0±3.7

30.8±2.8

Serum total cholesterol (mg dl−1)

174±38

178±41

134±26

160±35

Serum triglycerides (mg dl−1)

152±84

156±50

107±64

105±52

Serum HDL-cholesterol (mg dl−1)

46±10

48±18

41±11

47±9.2

Serum LDL-cholesterol (mg dl−1)

110±26

108±33

72±23

92±27

Serum uric acid (mg dl−1)

7.4±1.3

6.9±1.9

6.9±1.3

7.4±1.4

Serum potassium (mEq l−1)

4.2±0.4

4.4±0.3

4.9±0.7

4.9±0.6

Serum calcium (mg dl−1)

9.1±0.4

8.8±0.6

8.9±0.9

9.2±0.8

Serum phosphate (mg dl−1)

3.3±0.6

4.1±0.9

6.1±1.6

5.9±1.9

Serum intact PTH (pg ml−1)

50.3±31.3

78.5±49.3

148.6±143.4

136.0±148.1

Serum albumin (g dl−1)

4.0±0.5

3.7±0.4

3.9±0.3

3.9±0.3

Serum urea (mg dl−1)

28.6±12.9

37.6±19.6

64.4±16.0

61.8±17.3

Serum creatinine (mg dl−1)

1.6±0.8

2.5±1.7

12.1±3.0

10.2±2.2

Hemoglobin A1c (%)

5.6±1.1

5.9±1.2

5.4±0.6

5.6±1.0

Kt/V urea

1.33±0.21

1.55±0.20

  1. Abbreviations: BP, blood pressure; CKD, chronic kidney disease; CVD, cardiovascular disease; HD, hemodialysis; HDL, high-density lipoprotein; Kt/V, fractional urea clearance; LDL, low-density lipoprotein; PTH, parathyroid hormone.
  2. Variables are presented as mean±s.d. or number (percentage).